BioSpace News Archive

The global acute hospital care market is anticipated to grow tremendously during the forecast period. The reason for this is attributable to the increasing cases of chronic pain and growing number of patient volumes needing acute care.

OKYO Pharma Limited, a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced that the patent entitled “Methods of Lowering Blink Reflex for the Treatment of Dry Eye Disease” has been issued by the United States Patent and Trademark Office as U.S. Patent No. 11,197,906.

Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, announced that its Supervisory Board will propose the appointments of Mrs. Herna Verhagen and Mr. Sanjay Poonen as new members of the Supervisory Board at the Annual General Meeting of Shareholders, which will be held on May 10, 2022.

Numab Therapeutics AG and 3SBio Inc. announced that 3SBio’s subsidiary Sunshine Guojian Pharmaceutical Co., Ltd. exercised its option for an exclusive regional license for the development and commercialization of NM28, a potential best-in-class bivalent mesothelin -targeting CD3 T cell engager.

Antengene Corporation Limited announced that it presented results of the Company-sponsored, open-label Phase 1b TOUCH study with selinexor for the treatment of relapsed/refractory T and NK-Cell lymphoma, in a poster presentation at the 2021 ASH Annual Meeting, being held from December 11-14, 2021, both in Atlanta, Georgia and virtually.

ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals, announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis met its primary endpoint in a pre-specified interim analysis.

Onset is pleased to announce that Merck KGaA, Darmstadt, Germany has completed the process of integrating Onset’s InTemp monitoring solution into its global cold chain shipping operations.

Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments in Healthy Human Subjects.

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have entered into a license, development and commercialization agreement (the “agreement”) for Immatics’ TCR Bispecific candidate, IMA401.

OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2022 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 17, 2022.